5 results
reduction of fluid administration of 30%
The goal of this study is to prove whether kidney transplant recipients can reduce their risk of cardiovascular disease bij converting to Nulojix.
Here, we postulate that the balance between the effect of belatacept on regulatory T-cell function and the relative insensitivity of memory T-cells for belatacept leads to donor-specific alloreactivity. We plan to study the peripheral CD28-dependent…
Can administration of scopolaminebutyl from the start of the dying phase prevent death rattle during the dying phase?
Primary1. To evaluate patient and functional graft survival in stable renal transplant recipients (6-60 months post transplantation) converted from CNI to belatacept-based immunosupression as compared to those continuation of CNI based…